<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated by scripts/build-publications.mjs from data/publications.json. -->
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
  <title>The Peptide Current</title>
  <link>https://pepcurrent.com/</link>
  <atom:link href="https://pepcurrent.com/feed.xml" rel="self" type="application/rss+xml"/>
  <description>Plain-English peptide evidence, FDA status, risks, and unknowns—without products, protocols, or sourcing.</description>
  <language>en-us</language>
  <lastBuildDate>Sat, 25 Jul 2026 19:25:00 GMT</lastBuildDate>
  <generator>PepCurrent publication registry</generator>

  <item>
    <title>An advisory “yes” is not FDA approval. Here is the decision path.</title>
    <link>https://pepcurrent.com/guides/fda-peptide-vote-decoder.html</link>
    <guid isPermaLink="true">https://pepcurrent.com/guides/fda-peptide-vote-decoder.html</guid>
    <pubDate>Sat, 25 Jul 2026 19:25:00 GMT</pubDate>
    <description><![CDATA[A plain-language guide to what PCAC does, what the 503A Bulks List is, what the July votes changed, and what still requires a later FDA action.]]></description>
    <category>Field guide</category>
  </item>

  <item>
    <title>The Word After Phase 3 Is Not “Approved”</title>
    <link>https://pepcurrent.com/current/phase-3-is-not-fda-approval.html</link>
    <guid isPermaLink="true">https://pepcurrent.com/current/phase-3-is-not-fda-approval.html</guid>
    <pubDate>Sat, 18 Jul 2026 17:15:00 GMT</pubDate>
    <description><![CDATA[Issue 03 separates a trial result, an FDA application, product approval, and product identity—using CagriSema, retatrutide, and mazdutide as three different records rather than one “next GLP-1” bucket.]]></description>
    <category>Evidence literacy</category>
  </item>

  <item>
    <title>What 544 BPC-157 Papers Become in Humans</title>
    <link>https://pepcurrent.com/current/bpc-157-evidence-audit.html</link>
    <guid isPermaLink="true">https://pepcurrent.com/current/bpc-157-evidence-audit.html</guid>
    <pubDate>Sat, 18 Jul 2026 17:00:00 GMT</pubDate>
    <description><![CDATA[Issue 02 turns the paper count into an evidence funnel: one uncontrolled human musculoskeletal report, no controlled tendon-repair trial, and a regulatory review scoped much more narrowly than the online claims.]]></description>
    <category>Peptide Science</category>
  </item>

  <item>
    <title>The 14 peptide votes are in. Final FDA action is not.</title>
    <link>https://pepcurrent.com/current/fda-peptide-meeting-july-2026.html</link>
    <guid isPermaLink="true">https://pepcurrent.com/current/fda-peptide-meeting-july-2026.html</guid>
    <pubDate>Fri, 17 Jul 2026 00:30:00 GMT</pubDate>
    <description><![CDATA[All fourteen form-specific tallies are recorded from FDA’s exact questions and FDA-linked archived broadcasts. Six peptide groups were recommended for inclusion and emideltide against; every final FDA determination remains pending.]]></description>
    <category>Regulation</category>
  </item>

  <item>
    <title>BPC-157 was not “legalized.” Here is what changed.</title>
    <link>https://pepcurrent.com/archive/issue-01.html</link>
    <guid isPermaLink="true">https://pepcurrent.com/archive/issue-01.html</guid>
    <pubDate>Mon, 11 May 2026 16:00:00 GMT</pubDate>
    <description><![CDATA[Category 2 removal, the July advisory votes, and FDA's still-pending final determination are separate events. None verifies the identity or quality of an online product.]]></description>
    <category>Regulation</category>
  </item>
</channel>
</rss>
